Decitabine

Basic Information

Item Value
DrugBank ID DB01262
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 22

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 refractory cytopenia of childhood KG + DL
2 unclassified myelodysplastic syndrome KG + DL
3 partial deletion of the long arm of chromosome 5 KG + DL
4 aregenerative anemia KG + DL
5 bulbar polio KG + DL
6 severe congenital hypochromic anemia with ringed sideroblasts KG + DL
7 5q35 microduplication syndrome KG + DL
8 upper aerodigestive tract neoplasm KG + DL
9 neuralgic amyotrophy KG + DL
10 amyotrophic neuralgia KG + DL
11 Richter syndrome KG + DL
12 acute lymphoblastic/lymphocytic leukemia KG + DL
13 Ewing sarcoma KG + DL
14 metastatic neoplasm KG + DL
15 head and neck cancer KG + DL
16 blast phase chronic myelogenous leukemia, BCR-ABL1 positive KG + DL
17 malignant spiradenoma KG + DL
18 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma KG + DL
19 chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation KG + DL
20 refractory hematologic cancer KG + DL
21 bladder exstrophy-epispadias-cloacal exstrophy complex KG + DL
22 breast papillomatosis KG + DL

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). 本報告僅供研究參考,不構成醫療建議。

This site uses Just the Docs, a documentation theme for Jekyll.